For patients born with peroxisomal biogenesis disorders — a group of devastating inherited conditions that rob infants and children of neurological function — therapeutic options have historically amounted to little more than supportive care. The prospect of correcting the underlying genetic defect rather than managing its consequences represents a fundamental shift in how medicine might approach these conditions.
Published in the New England Journal of Medicine, this piece examines gene editing strategies targeting peroxisomal disorders, a class of diseases caused by mutations in PEX genes responsible for peroxisome assembly and function. Peroxisomes are essential organelles involved in fatty acid oxidation and plasmalogen synthesis; their dysfunction leads to toxic accumulation of very-long-chain fatty acids and progressive multisystem deterioration. The article explores how precision gene editing tools — likely including CRISPR-Cas9 or base-editing variants — are being evaluated as a means to restore functional peroxisome biogenesis at the cellular level, potentially halting or reversing disease progression in ways no current intervention can achieve.
Placing this in context, peroxisomal biogenesis disorders such as Zellweger spectrum disorder affect roughly 1 in 50,000 births and represent one of the more intractable frontiers in rare disease medicine. The broader gene-editing landscape has matured rapidly: ex vivo and in vivo delivery platforms — including adeno-associated viral vectors and lipid nanoparticles — are now enabling tissue-specific correction with increasing precision. The critical unknowns remain off-target editing rates, durability of correction in actively dividing cells, and the therapeutic window, since many affected children sustain irreversible neurological damage before diagnosis. This commentary-level piece from NEJM signals growing clinical momentum, but translation from bench to bedside for disorders with such narrow intervention windows will demand both technological refinement and accelerated neonatal screening infrastructure. Incremental but directionally important.